Literature DB >> 24480708

A molecular revolution in uveal melanoma: implications for patient care and targeted therapy.

J William Harbour1, Daniel L Chao2.   

Abstract

Uveal melanoma is the most common primary intraocular malignancy and has a strong propensity for fatal metastasis. Recent advances in the molecular genetics of uveal melanoma are revolutionizing our understanding of this cancer and the care of patients. The development of a new molecular classification of uveal melanoma based on a widely available 15-gene expression profile now allows patients at high risk of metastasis to be identified early so that individualized management can be offered. The recent discovery of major driver mutations in uveal melanoma provide a rational basis for development of new targeted therapies. Taken together, these advances are transforming our understanding and management of uveal melanoma with the ultimate goal of improving patient outcomes.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24480708      PMCID: PMC4047132          DOI: 10.1016/j.ophtha.2013.12.014

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  46 in total

Review 1.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

2.  Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.

Authors:  Jahan S Khalili; Xiaoxing Yu; Ji Wang; Brendan C Hayes; Michael A Davies; Gregory Lizee; Bita Esmaeli; Scott E Woodman
Journal:  Clin Cancer Res       Date:  2012-06-25       Impact factor: 12.531

3.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

4.  Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3.

Authors:  Marcel Martin; Lars Maßhöfer; Petra Temming; Sven Rahmann; Claudia Metz; Norbert Bornfeld; Johannes van de Nes; Ludger Klein-Hitpass; Alan G Hinnebusch; Bernhard Horsthemke; Dietmar R Lohmann; Michael Zeschnigk
Journal:  Nat Genet       Date:  2013-06-23       Impact factor: 38.330

5.  Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas.

Authors:  Michael D Onken; Amy Y Lin; Lori A Worley; Robert Folberg; J William Harbour
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

6.  Survival rates with uveal melanoma in the United States: 1973-1997.

Authors:  Arun D Singh; Allan Topham
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

7.  Effectiveness of treatments for metastatic uveal melanoma.

Authors:  James J Augsburger; Zélia M Corrêa; Adeel H Shaikh
Journal:  Am J Ophthalmol       Date:  2009-04-17       Impact factor: 5.258

8.  Oncogenic mutations in GNAQ occur early in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-21       Impact factor: 4.799

9.  Selumetinib shows promise in metastatic uveal melanoma.

Authors: 
Journal:  Cancer Discov       Date:  2013-06-06       Impact factor: 39.397

10.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

View more
  28 in total

Review 1.  Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

Authors:  Jun Guo; Shukui Qin; Jun Liang; Tongyu Lin; Lu Si; Xiaohong Chen; Zhihong Chi; Chuanliang Cui; Nan Du; Yun Fan; Kangsheng Gu; Fang Li; Junling Li; Yongheng Li; Houjie Liang; Jiwei Liu; Man Lu; Aiping Lu; Kejun Nan; Xiaohui Niu; Hongming Pan; Guoxin Ren; Xiubao Ren; Yongqian Shu; Xin Song; Min Tao; Baocheng Wang; Wenbin Wei; Di Wu; Lingying Wu; Aiwen Wu; Xiaolin Xu; Junyi Zhang; Xiaoshi Zhang; Yiping Zhang; Huiyan Zhu
Journal:  Ann Transl Med       Date:  2015-12

Review 2.  Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?

Authors:  Oriol Yélamos; Pedram Gerami
Journal:  Melanoma Manag       Date:  2015-08-10

3.  Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker.

Authors:  J William Harbour; Manuel Paez-Escamilla; Louis Cai; Scott D Walter; James J Augsburger; Zelia M Correa
Journal:  Am J Ophthalmol       Date:  2018-09-07       Impact factor: 5.258

4.  BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas.

Authors:  Matthew G Field; Jeffim N Kuznetsov; Parker L Bussies; Louie Z Cai; Karam A Alawa; Christina L Decatur; Stefan Kurtenbach; J William Harbour
Journal:  Clin Cancer Res       Date:  2019-07-08       Impact factor: 12.531

5.  Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Authors:  Hanyin Cheng; Vivian Chua; Connie Liao; Timothy J Purwin; Mizue Terai; Ken Kageyama; Michael A Davies; Takami Sato; Andrew E Aplin
Journal:  Mol Cancer Ther       Date:  2017-01-30       Impact factor: 6.261

Review 6.  Recent developments in prognostic and predictive testing in uveal melanoma.

Authors:  Matthew G Field; J William Harbour
Journal:  Curr Opin Ophthalmol       Date:  2014-05       Impact factor: 3.761

Review 7.  Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.

Authors:  Vivian Chua; Dominic Lapadula; Clinita Randolph; Jeffrey L Benovic; Philip B Wedegaertner; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2017-02-21       Impact factor: 5.852

Review 8.  Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.

Authors:  K Rai; R Pilarski; C M Cebulla; M H Abdel-Rahman
Journal:  Clin Genet       Date:  2015-07-14       Impact factor: 4.438

9.  PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Authors:  Matthew G Field; Christina L Decatur; Stefan Kurtenbach; Gülçin Gezgin; Pieter A van der Velden; Martine J Jager; Kaleigh N Kozak; J William Harbour
Journal:  Clin Cancer Res       Date:  2016-03-01       Impact factor: 12.531

10.  Tumour Expression of Histone Deacetylases in Uveal Melanoma.

Authors:  Louis Levinzon; Michele Madigan; Vuong Nguyen; Enisa Hasic; Max Conway; Svetlana Cherepanoff
Journal:  Ocul Oncol Pathol       Date:  2018-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.